Results 51 to 60 of about 81,709 (149)

Immuno-Augmentative Therapy [PDF]

CA: A Cancer Journal for Clinicians, 1984
openaire   +3 more sources

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency

Biologics: Targets & Therapy, 2009
Irina Petrache1, Joud Hajjar1, Michael Campos21Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Miller School of Medicine ...
Irina Petrache, Joud Hajjar, Michael Campos   +2 more
doaj  

Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy

Therapeutic Advances in Respiratory Disease, 2012
Objective: Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization.
Juan Carlos Barros-Tizón, María Luisa Torres, Ignacio Blanco, María Teresa Martínez,   +4 more
doaj   +1 more source

The Role of Alpha-1 Antitrypsin in the Pathophysiology and Treatment of Inflammatory Lung Diseases

Journal of Inflammation Research
Daniella A Spittle,1 Alice M Turner2 1Department of Inflammation and Ageing, University of Birmingham, Birmingham, UK; 2Department of Applied Health Sciences, University of Birmingham, Birmingham, UKCorrespondence: Alice M Turner, Email a.m.turner@bham ...
Spittle DA, Turner AM
doaj  

Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint. [PDF]

Eur Respir Rev, 2023
Miravitlles M, Anzueto A, Barrecheguren M.   +2 more
europepmc   +1 more source

Antitrypsin deficiency: still more to learn about the lung after 60 years

ERJ Open Research
The past 60 years have seen multiple publications related to lung disease in α1-antitrypsin deficiency largely reflecting the pathophysiology, biochemical effect and outcomes of augmentation therapy.
Robert A. Stockley, David G. Parr
doaj   +1 more source

Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa. [PDF]

Mol Ther, 2023
Occelli LM, Zobel L, Stoddard J, Wagner J, Pasmanter N, Querubin J, Renner LM, Reynaga R, Winkler PA, Sun K, Marinho LFLP, O'Riordan CR, Frederick A, Lauer A, Tsang SH, Hauswirth WW, McGill TJ, Neuringer M, Michalakis S, Petersen-Jones SM.   +19 more
europepmc   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

PCN Reports
Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient.
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
doaj   +1 more source

Agmatine augmentation in treatment-resistant obsessive-compulsive disorder: a prospective open-label case series

Frontiers in Psychiatry
ImportanceObsessive-compulsive disorder (OCD) remains treatment-resistant in 40-60% of patients despite adequate trials of serotonin reuptake inhibitors and cognitive behavioral therapy.
Joshua D. Salvi, Joshua D. Salvi
doaj   +1 more source

Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics. [PDF]

Chronic Obstr Pulm Dis, 2023
Strange C, Allison S, McCathern J, Sandhaus RA, Holm KE.   +4 more
europepmc   +1 more source